AbbVie Inc. (NYSE:ABBV)

Top Dividend Pharmaceutical Stocks Safe Bet for Rest of 2017

One thing that crept on the radar screen last week is that after eight years of a bull market, five of which are of the secular variety, after the S&P 500 ...
Read Full Story »

Short Sellers Run for Cover From Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Major Pharma Short Sellers Couldn’t Make Up Their Minds Before Failed Trump Health Care Vote

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Back Off Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AbbVie, KLA-Tencor, Marathon Oil, Verifone and Many More

Stocks were indicated higher ahead of Friday's key payrolls and unemployment report, but there has been a softer tone in recent days as some selling has taken place. The bull ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AbbVie, Frontier Communications, Hyatt Hotels, Weatherford International and Many More

Stocks were indicated to open marginally lower on Tuesday. Now that the bull market is officially eight years old, 24/7 Wall St. took a look at the then versus now headlines with ...
Read Full Story »
Prescription drugs

Why Short Sellers Are Making a Massive Bet in Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
investing

Jefferies Makes Another Huge Change to Franchise Picks Portfolio

Most of the top firms we cover here at 24/7 Wall St. are tweaking their high-conviction stocks lists for 2017, and many are trying to take into account macro changes ...
Read Full Story »
Pair of dice

Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
refinery

Jefferies Adds Big Dividend-Paying Leader to Franchise Picks List

As we head deeper into February, many of the top firms we cover here at 24/7 Wall St. are tweaking their high-conviction stock lists for 2017, and many are trying ...
Read Full Story »
white pills

AbbVie Slides on Mixed Q4 Earnings

When AbbVie Inc. (NYSE: ABBV) reported its fourth-quarter financial results before the markets opened on Friday, it posted $1.20 in earnings per share (EPS) and $6.8 billion in revenue. Consensus ...
Read Full Story »
Prescription drugs

Short Sellers Run for Cover From Major Pharma

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
Good heart health

What to Expect From Major Health Care Stocks Reporting This Week

As January comes to a close, we are in the heart of earnings season, when most companies report and set a direction for the market. Dow 20,000 has been reached but ...
Read Full Story »
research

Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017

While the run since the Trump election and now the inauguration has been solid, there are some storm clouds on the horizon. Volatility has drifted to historic lows, while price-to-earnings ...
Read Full Story »
ThinkstockPhotos-475180302

7 Key Earnings Coming This Week

24/7 Wall St. has put together a preview of some of the major companies scheduled to share their quarterly results in the coming days, as we are in the heart of ...
Read Full Story »